Objectives: Healthcare workers (HCWs) are a trusted source of vaccine-related information for patients and communities, but they can show hesitancy or reluctance towards vaccinations. The objective of our study was to investigate HCWs' sentiment and hesitancy towards vaccination, focusing on COVID-19 and influenza vaccination.
Study Design: A global cross-sectional study spanning four continents.
The recently developed V79-RBEbiological weighting function (BWF) model is a simple and robust tool for a fast relative biological effectiveness (RBE) assessment for comparing different exposure conditions in particle therapy. In this study, the RBEderived by this model (through the Particle and Heavy Ion Transport code System (PHITS) simulated d(y) spectra) is compared with values of RBEusing experimentally derived d(y) spectra from a silicon-on-insulator (SOI) microdosimeter. Approach: Experimentally measured d(y) spectra are used to calculate an RBEvalue utilizing the V79-RBEBWF model as well as the modified microdosimetric kinetic model (MKM) to produce an RBE-vs-ytrend for a wide range of ions.
View Article and Find Full Text PDFBackground: Patients with psychiatric disorders experience a reduced quality of life also due to the antipsychotic drugs assumed, that negatively affects their cognitive abilities. A healthy lifestyle, such as physical activity, can improve both functional abilities and mental health of patients with a dual diagnosis, psychiatric and cognitive. Despite this knowledge, these people are more sedentary than the general population, probably because of their apathy, core aspects of the illness.
View Article and Find Full Text PDFBackground: As an extended analysis of the COVID-DELAY study, we aimed to assess the impact of the COVID-19 pandemic on diagnosis, staging, and survival outcomes among patients with colorectal cancer (CRC) diagnosis performed from 2019 to 2022.
Methods: All consecutive newly diagnosed CRC patients referred to 11 Italian Oncology Departments between March and December 2019, 2020, 2021, and 2022 were enrolled. Access rate, demographics, diagnostic-therapeutic temporal intervals, and first-line progression-free survival (PFS) and OS among metastatic patients were assessed.